On Tuesday shares of OvaScience, Inc. (NASDAQ:OVAS) closed at $34.73. OvaScience, Inc. (NASDAQ:OVAS) on March 28, 2015, declared that additional clinical experience of the Company’s AUGMENTSM treatment demonstrated improved pregnancy rates in women who had failed three to seven prior in vitro fertilization (IVF) cycles.
The Coca-Cola Company (NYSE:KO) in last trading activity moved up 0.10% to close at $40.55. Company weekly performance is 0.20% while its quarterly performance stands at -4.61%. The Coca-Cola Company (NYSE:KO) is -9.14% away from its 52 week high. Coca-Cola Amatil Indonesia (CCAI), part of US beverage manufacturer The Coca-Cola Company (NYSE:KO), expects to boost production with an investment of US$500 million.
On last trading day Synovus Financial Corporation (NYSE:SNV) moved down -0.39% to close at $28.01. Its volatility for the week is 1.45% while volatility for the month is 1.69%. SNV’s sales growth for past 5 years was -9.30% and its EPS growth for past 5 years was 15.40%. Synovus Financial Corporation (NYSE:SNV) monthly performance is 0.36%. Synovus Financial Corp. (NYSE:SNV) announced that it has received 19 Greenwich Customer Service Excellence awards in Middle Market and Small Business Banking from Greenwich Associates.
Kate Spade & Company (NYSE:KATE) has 0.60% insider ownership while its institutional ownership stands at 99.80%. In last trading activity company’s stock closed at $33.39. Good news for fashion lovers: Handbag and apparel retailer Kate Spade & Co. plans to open its outlet store at Opry Mills this week. Kate Spade & Company (NYSE:KATE) outlet is set to open Friday in the fashion wing near the Janie and Jack outlet.
On last trading day Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) moved up 2.81% to close at $50.15. Its volatility for the week is 4.88% while volatility for the month is 5.87%. KYTH’s EPS growth for past 5 years was 11.10%. Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) monthly performance is 24.29%. With the drug poised for FDA approval, Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH), the company that developed it, says dermatologists could be using it on patients later this year.